Nominations for New Members for the Department of Health and Human Services (HHS) Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission in the United States
The HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission in the United States (the Panel) is accepting nominations for a new community representative with expertise in HIV in women and prevention of mother to child HIV transmission (PMTCT). The Panel welcomes diversified representation in the community membership, which reflects the demographics of the current HIV epidemics in the United States. The community member may assist the Panel in identifying and addressing unique treatment aspects that relate to the constituency he or she represents. The candidate shall have knowledge of and involvement with issues related to the management of HIV-infected pregnant women and PMTCT as evidenced by experience in HIV treatment education/advocacy or clinical/public policy initiatives related to HIV treatment. The successful candidates shall serve a 3-year term, with potential for reappointment, beginning in April or May 2013.
The Panel is a Working Group of the Office of AIDS Research Advisory Council (OARAC) of the National Institutes of Health (NIH). It is comprised of approximately 25 members who are clinicians, researchers, academicians, and HHS representatives with expertise in the management of pregnant HIV-infected women (with training in either obstetrician/gynecologists or women’s health, or nursing with expertise in women’s health) and interventions for PMTCT (e.g., pediatric specialists in HIV infection), as well as community representatives with knowledge of HIV infection in pregnant women and interventions for PMTCT.
The Panel meets monthly via teleconference and occasionally face-to-face to review and critically evaluate emerging scientific data relating to antiretroviral therapy in pregnant women and interventions for PMTCT to update of the Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States, which is found at http://AIDSinfo.nih.gov.
Panel members are not compensated for their time commitment and travel support is not provided for participation.
The nomination should include a curriculum vitae and a letter of nomination (or letter of interest) that contains specific references to how the nominee would contribute to the work of the Panel. Please submit nominations by March 22, 2013 to Lynne M. Mofenson, M.D., Executive Secretary, National Institute of Child Health and Human Development, National Institutes of Health, 6100 Executive Blvd, Room 4B11, Rockville, MD 20852, phone: 301-435-6870; email: LM65D@nih.gov.